Extensively drug-resistant tuberculosis
MONDO:0100482A type of drug-resistant tuberculosis that is resistant to any fluoroquinolone, and at least one of three second-line injectable drugs (capreomycin, kanamycin, and amikacin), in addition to resistance to rifampicin and isoniazid.
Also known as: XDR-TB
11 clinical trials for this condition and its sub-types.
Follow this condition — get notified about new trialsBroader categories
-
Lung valves could starve Drug-Resistant TB cavities
Disease control Not yet recruitingThis study tests whether placing one-way valves in the lungs can shrink cavities caused by drug-resistant tuberculosis (TB) or nontuberculous mycobacteria (NTM) infections. The valves block airflow into the cavity, creating a low-oxygen environment that may slow or stop bacterial…
Phase: NA • Sponsor: Azienda Ospedaliero-Universitaria Careggi • Aim: Disease control
Last updated Jun 27, 2026 08:05 UTC
-
A mobile x-ray van with AI could spot TB before it spreads
Diagnosis Not yet recruitingThis study tests a community-based screening strategy for tuberculosis (TB) in migrant communities in New York City. A mobile van offers digital chest X-rays with AI interpretation, along with TB symptom checks, blood tests for latent TB, and HIV testing. The goal is to see wheth…
Phase: NA • Sponsor: Columbia University • Aim: Diagnosis
Last updated Aug 01, 2026 00:00 UTC
-
Could a tongue swab replace sputum tests for TB?
Diagnosis Not yet recruitingThis large study in five countries will test new, portable diagnostic tools for tuberculosis (TB) that use tongue swabs and AI-assisted chest X-rays. The goal is to see if these faster, easier tests can find more TB cases, especially in people who have no symptoms or can't produc…
Phase: NA • Sponsor: Liverpool School of Tropical Medicine • Aim: Diagnosis
Last updated Jun 27, 2026 12:05 UTC
-
Can immune profiling unlock the hidden stages of tuberculosis?
Knowledge-focused Not yet recruitingThis study aims to better understand tuberculosis (TB) across its entire spectrum—from early, symptom-free infection to active disease and after treatment. Researchers will recruit TB patients and their close contacts to analyze immune responses and identify biomarkers that could…
Sponsor: Irene Latorre Rueda • Aim: Knowledge-focused
Last updated Aug 01, 2026 00:00 UTC